Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (MRI-derived liver iron content) and biologically active iron (enhanced labile plasma iron; eLPI) on post-transplantation outcomes in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogenic HCT. Methods The prospective, multicentre, observational, ALLogeneic Iron inVEstigators (ALLIVE) trial recruited patients at five centres in Germany. We enrolled patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogeneic HCT. Patients underwent cytotoxic conditioning for a median of 6 days (IQR 6-7) before undergoing allogeneic HCT and were followed up for up to 1 year (±3 months) post-transplantation. eLPI was measured in serum samples with the FeROS eLPI kit (Aferrix, Tel-Aviv, Israel) and values greater than 0·4 μmol/L were considered to represent raised eLPI. Liver iron content was measured by MRI. The primary endpoints were the quantitative delineation of eLPI dynamics during allogeneic HCT and the correlation coefficient between liver iron content before HCT and dynamic eLPI (eLPI dyn ; maximum eLPI minus baseline eLPI). All patients with available data were included in all analyses. This is the final analysis of this completed trial, which is registered with ClinicalTrials.gov, number NCT01746147. Findings Bet…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
(2015) · Postgraduate Haematology · doi:10.1002/9781118853771.ch51 · Cited by 3,290
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Gooley, T. A., Chien, J. W., Pergam, S. A., Hingorani, S., Sorror, M. L., Boeckh, M., Martin, P. J., Sandmaier, B. M., Marr, K. A., Appelbaum, F. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004383 · Cited by 1,493
Non-invasive assessment of hepatic iron stores by MRI
Gandon, Y., Olivié, D., Guyader, D., Aubé, C., Oberti, F., Sebille, V, & Deugnier, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15436-6 · Cited by 671
Non-transferrin bound iron: a key role in iron overload and iron toxicity
Brissot, P., Ropert, M., Le Lan, C., & Loréal, O. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.014 · Cited by 654
Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major
Angelucci, E., Brittenham, G. M., McLaren, C. E., Ripalti, M., Baronciani, D., Giardini, C., Galimberti, M., Polchi, P., & Lucarelli, G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430503 · Cited by 607
Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity
Hershko, C., Graham, G., Bates, G. W., & Rachmilewitz, E. A. (1978) · British Journal of Haematology · doi:10.1111/j.1365-2141.1978.tb03662.x · Cited by 423
Craven, C. M., Alexander, J., Eldridge, M., Kushner, J. P., Bernstein, S., & Kaplan, J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3457 · Cited by 259
Vento, S., Cainelli, F., & Cesario, F. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70437-6 · Cited by 211
Cited by
Iron in infection and immunity
Nairz, M., & Weiss, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100864 · Cited by 359
Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 235
Self-citationIron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
“In addition, non-protein bound labile iron, not detectable in healthy individuals, can occur in the extracellular space in malignancies, especially in patients with acute myeloid leukemia or myelodysplastic syndrome (MDS) during conditioning for allogenic hemopoietic stem cell transplantation (144, 145).”
BackgroundWeber, S., Parmon, A., Kurrle, N., Schnütgen, F., & Serve, H. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.627662 · Cited by 94
“Keywords: myelodysplastic syndrome, acute myeloid leukemia, iron overload, reactive oxygen species, microenvironment, iron chelation Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; DFS, disease-free survival; GvHD, graftversus-host disease; HFE, hereditary hemochromatosis protein; HSCT,…”
BackgroundResultInfluentialMolecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
Zhao, Y., Huang, Z., & Peng, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743006 · Cited by 67
Metadata
- Authors
- Wermke, M., Eckoldt, J., Götze, K. S., Klein, S. A., Bug, G., de Wreede, L. C., Kramer, M., Stölzel, F., von Bonin, M., Schetelig, J., Laniado, M., Plodeck, V., Hofmann, W.-K., Ehninger, G., Bornhäuser, M., Wolf, D., Theurl, I., & Platzbecker, U.
- Affiliations
- University Hospital Carl Gustav Carus (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- University Medical Centre Mannheim (DE)
- University Hospital Frankfurt (DE)
- Innsbruck Medical University (AT)
- Corresponding author
- Wermke, Martin
- ORCID
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 5
- Issue
- 5
- Pages
- e201-e210
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2796455901
- Cited by
- 59
- References
- 34
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 6
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Haematology (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- iron overload, acute myeloid leukemia, myelodysplastic syndrome, liver iron concentration, magnetic resonance imaging, non-relapse mortality, graft-versus-host disease, post-transplant infection, conditioning regimen, prognostic factors
- MeSH terms
- Aged, Female, Humans, Iron, Liver, Male, Middle Aged, Myelodysplastic Syndromes, Prospective Studies, Transplantation, Homologous, Leukemia, Myeloid, Acute, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30036-x
- The paper
- Wermke, M., Eckoldt, J., Götze, K. S., Klein, S. A., Bug, G., de Wreede, L. C., Kramer, M., Stölzel, F., von Bonin, M., Schetelig, J., Laniado, M., Plodeck, V., Hofmann, W.-K., Ehninger, G., Bornhäuser, M., Wolf, D., Theurl, I., & Platzbecker, U. (2018). Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30036-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.